Kornimate/medical-research-clean huggingface dataset:
electronic neurocognitive tools in screening for mental capability in patients undergoing liver surgery

Conditions: Liver and Intrahepatic Bile Duct Disorder

Summary: this trial studies how well electronic neurocognitive tools work in screening for mental capability in patients who are undergoing liver surgery. using electronic neurocognitive screening tools may help to better assess mental impairment.

primary objectives: i. evaluate feasibility of the electronic batteries, measured by the completion rate and time to completion of the batteries. secondary objectives: i. comparison of the completion rate and time to completion between the written and electronic batteries. ii. comparison of the scoring distribution between the screening tools. exploratory objectives: i. assess if a history of mental or cognitive illness or ongoing treatment with neuropsychiatric medications impact the ability to complete written and/or electronic neurocognitive screening. outline: patients are randomized to 1 of 2 groups. group i: patients receive the braincheck cognitive assessment over 15 minutes followed by the paper and pen cognitive assessment within 2 months prior to surgery and within 2 months after surgery. group ii: patients receive the paper and pen cognitive assessment followed by the braincheck cognitive assessment over 15 minutes 2 months prior to surgery and within 2 months after surgery.

Eligibility criteria:
inclusion criteria: * all english-speaking patients undergoing hepatectomy at main campus university of texas (ut)-md anderson cancer center who are cognitively able to provide informed consent in the opinion of the attending physician.
study of azd3152 intramuscular injection or intravenous infusion in healthy japanese adult participants

Conditions: COVID-19, SARS-CoV-2

Summary: azd3152 is being evaluated for administration to prevent covid-19. this phase i study will gather important information on the safety and tolerability of azd3152 as well as relevant data on the pk, pd (as the neutralising responses against sars-cov-2) profile and the generation of ada to azd3152.

this is a phase i, randomised, double-blind, placebo controlled study evaluating the safety, tolerability, pk and pd of azd3152 in healthy japanese adult participants, 18 to 55 years of age. approximately 24 healthy participants will be randomised at up to 2 study sites.

Eligibility criteria:
inclusion criteria: * japanese men and women and 18 to 55 years of age inclusive, at the time of signing the informed consent. * no positive results of sars-cov-2 nat and/or rapid antigen tests. * healthy participants by medical history, physical examination, baseline safety laboratory studies, and screening parameters, according to the judgement of the investigators, with no concomitant disease or concomitant medication. * ecg without clinically significant abnormalities. * able to complete the follow-up period through day 361 as required by the protocol. * body weight ≥ 45 kg and ≤ 110 kg and bmi ≥ 18.0 to ≤ 30.0 kg/m2. exclusion criteria: * known hypersensitivity to any component of the imp. * history of allergic disease or reactions likely to be exacerbated by any component of the imp. * previous hypersensitivity, infusion related reaction or severe adverse reaction following administration of mabs. * fever above 38.0°c on day prior to or on day of randomisation/dosing. * ast, alt or serum creatinine above uln; bilirubin and alp \>1.5 × uln. * any vaccination except for covid-19 vaccine (e.g., inactivated influenzae vaccine) planned. * sars cov-2 or covid-19: receipt of a covid-19 vaccine within 3 months. covid-19 infection within 3 months prior.
vortioxetine to prevent return of symptoms in children with depression

Conditions: Depression

Summary: the purpose of this study is to find out if vortioxetine is better than placebo (sugar pills) in preventing depression in children who improved when treated with vortioxetine.

the study consists of a 12-week open-label, flexible-dose treatment period with vortioxetine, followed by a 26-week, randomized, double-blind, fixed-dose, placebo-controlled relapse-prevention period. there will be a safety follow up 4 weeks after the end of the 26-week double-blind treatment period. the study population will include 'de novo' participants as well as 'rollover' participants from other paediatric vortioxetine studies 12709a (nct02709655) and 12712a (nct02871297), who, in the investigator's opinion, could benefit from continued treatment with vortioxetine.

Eligibility criteria:
inclusion criteria: de novo participants * the participant has a primary diagnosis of mdd according to dsm-5™ although co-morbid anxiety disorders will be permitted (except post traumatic stress disorder (ptsd) and obsessive compulsive disorder (ocd)). * the participant has a cdrs-r total score ≥45 at the screening and baseline visits. * the participant has a clinical global impression - severity of illness (cgi-s) ≥4 at the screening and baseline visit exclusion criteria: * the participant receives ongoing current psychotherapy that is planned to be intensified. interpersonal psychotherapy (ipt) or cognitive behavioural therapy (cbt) are not allowed. * the participant presents with, or has a history of, an axis i (dsm-5tm) diagnosis of bipolar disorder, ptsd, ocd, autism, pervasive developmental disorder (pdd), or schizophrenia or schizoaffective disorder. * the participant has a diagnosis of attention-deficit/hyperactivity disorder (adhd) and is not maintained on a stable dose of a methylphenidate or amphetamine for a minimum of 4 weeks prior to the study treatment. * the participant has attempted suicide or is at significant risk of suicide other inclusion and exclusion criteria may apply.
study of natural course progression of diabetic retinopathy

Conditions: Biomarkers of Diabetic Retinopathy

Summary: the goal of this observational study is to observe the formation and development of the non-perfusion area of diabetic retinopathy in the posterior area of the retina in type 2 diabetes patients aged 18-75 years old, who can cooperate with all examinations and sign informed consent, clinical myopathy examination and optos 7 field of vision with mild than severe npdr, and no other exclusion indicators.the main questions it aims to answer are whether posterior retinal non-perfusion area occurs earlier than peripheral non-perfusion area and whether the rate of non-perfusion area expansion is a risk factor for the progression of diabetic retinopathy. participants will have protocol-specific follow-up examinations at 1, 2, 3, 4, and 5 years (± 3 months). additional visits are made as required by the study and the patient's condition. the contents of follow-up examinations are: history of other diseases, medications being used, eye diseases, surgeries, treatments, height, weight, and blood pressure. best corrected vision, logarithmic visual acuity chart. tupai octa, 24×20mm range, 6×6mm range scan. optos fundus imaging, color and no red light images. fundus fluorescence angiography (only preliminary examination for the first time found mild to moderate npdr patients, who have been angiographed in the past, only at the 5th year, or as required by the condition). glycosylated hemoglobin. creatinine, urea, glomerular filtration rate. total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol. urinary microalbumin/urinary creatinine acr. microvisual field.


Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes aged 18-75 years * can cooperate with the inspection and sign the informed consent * there are no other eye diseases that cause retinal neovascularization * there is no known substantial media haze that would hinder fundus image acquisition * no history of fundus laser treatment or no possibility of laser treatment expected within six months * no previous history of intravitreal drug injection, and no intravitreal drug injection is expected in the next 6 months * macular edema without diabetes (zeiss oct women \< 290µm, male \< 305µm; oct female in heidelberg is \< 305µm, and for males \< 320µm) * in the field of visual field of clinical mydriasis and optos photo 7 field of view, dr lesions were less severe than npdr * no history of eye surgery exclusion criteria: * patients with kidney failure. * history of systemic anti-vegf therapy within the last month. * follow-up is expected to be difficult or patients from other provinces have traction retinal detachment; * the patient has a history of allergy
sustaining women's smoking cessation postpartum

Conditions: Lung Diseases; Cardiovascular Diseases; Heart Diseases

Summary: to conduct a five-year demonstration and education project to sustain smoking cessation postpartum by women who had stopped smoking in pregnancy.

background: the results from this study were expected to demonstrate the effectiveness of a practical program to protect women and their families from direct and indirect smoke exposure and to contribute longitudinal data on change processes involved in smoking cessation, especially those over the maintenance, relapse, and recycling stages, in a relatively complete population through a critical transition. design narrative: the tlc program, unique in its focus on the postpartum period, used a researched model of behavior change that matched messages and skill training with the woman's stage of change. it also addressed the whole family to create a supportive environment for individual change, included other steps for families to protect children from passive smoke and negative modeling, and focused on smoking and smoke exposure directly as well as through self-care and child-care messages. the program used innovative materials, including videotapes and intervention. the study took place in two multi-ethnic health-care sites where the research team had conducted previous studies. the study used a randomized mixed design with 500 women who smoked regularly before pregnancy and who had been abstinent for \> 30 days at their 28th week of pregnancy. the primary outcome was abstinence at one year postpartum. secondary outcomes were partner smoking status and exposure of the index baby. self report was validated biochemically in samples of mothers and babies. the study design separated data collection from the experiments by enrolling subjects in a university-sponsored study of new mothers' health-care site.

Eligibility criteria:
no eligibility criteria
safety study of the inhibition of agouti-related protein (agrp) for the management of obesity and weight loss

Conditions: Obesity

Summary: multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. one of the most studied pathways involves the melanocortin receptor. agouti-related protein (agrp) and alpha-melanocyte stimulating hormone (alphamsh)have been shown to play an integral role in food intake and body weight. it is reasonable to speculate that if there is an imbalance of alphamsh and agrp exist in obese individuals and inhibiting the activity of agrp may be of therapeutic benefit in treating obesity.


Eligibility criteria:
inclusion criteria: * male or female volunteers, aged 18 to 65 years, inclusive. * subjects must be obese (class 1: bmi of 30.0 to 34.9 kg/m2 or class 2: bmi of 35 to 39.9 kg/m2 in non-asians and bmi of 27.0 - 31.9 kg/m2 or 32.0 - 36.9 kg/m2 in asians) at the screening visit. * female subjects must be postmenopausal (with amenorrhea for at least 2 years prior to scheduled dosing and confirmatory fsh test in the range of 23-116 iu/l) or surgically sterile (with physician or insurance documentation of bilateral tubal ligation at least 6 months prior to screening visit or of a hysterectomy and/or bilateral oophorectomy) and agree not to undergo in vitro fertilization during the study and for 6 months post treatment. exclusion criteria: * type 1 diabetes. * type 2 diabetes. * history of myocardial infarction, stroke, including transient ischemic attack, in the last 2 years. * asthma or chronic obstructive pulmonary disease controlled by regular use of inhaled steroids. * subjects with rheumatoid arthritis, lupus, or multiple sclerosis regularly requiring steroids or disease-modifying anti-rheumatic agents. * subjects with psoriasis requiring oral steroids. * subjects planning to undergo gastric bypass or resection surgery, or who have had such a procedure in the 6 months prior to the screening visit.

Keywords: obesity class 1 class 2 weight loss agrp ttp435 alphamsh agouti-related protein alpha-melanocyte stimulating hormone
effects of sevoflurane and ketamine on qt in electroconvulsive therapy

Conditions: Major Depression; Electroconvulsive Therapy

Summary: the aim of this study was to evaluate the effect of sevoflurane or ketamine on the qtc and tp-e interval during in patients with major depression.

patients enrolled in the study are randomly allocated by computer-generated random numbers to receive either sevoflurane or ketamine for their initial ect session. they subsequently receive an alternative study drug in their next session, continuing to alternate between drugs at each session until the sixth session. in group s, sevoflurane are initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus is delivered, in group k, ketamine are given to 1mg/kg ıv bolus. electrical stimulus is delivered via bilateral frontotemporal electrodes.the mean arterial pressure (map), hr, and ecg are recorded before anesthetic induction (t1), after anesthetic induction (t2) and at 0, 1, 3, 10 min after the seizure ended (t3, t4, t5 and t6, respectively).the qt interval and tp-e interval are measured by one author, who was unaware of group allocation.

Eligibility criteria:
inclusion criteria: * unpremedicated * american society of anesthesiologists (asa) i-ii the patients * major depressions patients scheduled for ect sessions exclusion criteria: * pregnant * with permanent pacemakers, * diabetes mellitus, * atrial fibrillation, * electrolyte imbalance, * patients taking antiarrhythmics and β-blockers.

Keywords: sevoflurane ketamine qt interval
surgery alone versus methotrexate before surgery in cesarean scar pregnancy

Conditions: Cesarean Scar Pregnancy

Summary: there are no universal treatment guidelines available. the ultimate purpose of the management of csp is to simultaneously remove the pregnancy and successfully preserve the woman's fertility (gonzalez \& tulandi, 2017). a variety of medical and surgical treatment modalities for csp have been reported; however, most of these are based on low-level evidence(sun et al., 2019).

this will be a randomized clinical trial to evaluate the effect of administration of methotrexate before surgery in reducing bleeding, injury to bladder and ureter, operative time and removing of csp mass.this will be in comparison to surgery alone in cases of first trimester cesarean scar pregnancy

Eligibility criteria:
inclusion criteria:• * gestational age before 13 w * past history of 1 or more cs * presence of gs implanted on cesareans scar exclusion criteria: * presence of severe vaginal bleeding (emergency) * previous history of uterine surgery other than cs * the whole mass is interior and the bulge is more in the cavity * bleeding disorder * patient not candidate for methotrexate (positive fetal heart pulsation, * patient refuse to participate in the study

Keywords: cesarean scar pregnancy, methotrexate, miscarriage, ectopic pregnancy
a study to assess the role of fenofibrate in preventing ischemic cholangiopathy after liver transplantation

Conditions: Liver Transplant

Summary: the purpose of this study is to evaluate the safety and effectiveness of a once-daily medication, fenofibrate (lofibra), to prevent ischemic cholangiography (ic) in persons who were transplanted with livers donated after circulatory death (dcd).

in this prospective pilot study, we aim to evaluate 1) the tolerability and safety, 2) the efficacy of 12 weeks once-daily fenofibrate in reducing ic incidence after dcd liver transplantation, 3) assess the association between serum markers of cholestasis and development of ic.

Eligibility criteria:
inclusion criteria: * patients who have undergone donation after circulatory death (dcd) liver transplantation (lt). * at least one serum alkaline phosphatase level \>2.5x upper limit of normal between post-lt days 21-60 (inclusive). exclusion criteria: * lt performed for primary sclerosing cholangitis or primary biliary cholangitis. * untreated hepatic artery compromise (e.g thrombosis, stenosis) * untreated biliary anastomotic stricture or bile leak between days 0-60 after lt * renal dysfunction defined as baseline glomerular filtration rate \< 30 ml/min. * previously known intolerance or allergy to fenofibrate. * other clinically significant comorbid condition, including psychiatric conditions, which in the opinion of the study team, may interfere with patient treatment, safety, assessment, or compliance with the treatment.

Keywords: ischemic cholangiography
comparison of nerve-sparing techniques in radical prostatectomy for oncological outcome and functional recovery.

Conditions: Prostate Cancer

Summary: to evaluate the difference among three nerve-sparing techniques(unilateral intrafascial resection, bilateral intrafascial resection, bilateral extrafascial resection) of oncological outcome and functional recovery.

surgery is a common and effective treatment for localized prostate cancer. the main objective of surgical treatment is to remove the tumor completely in order to achieve the goal of cure. intrafascial nerve-sparing radical prostatectomy is a radical resection of prostate cancer with minimal damage to the nerves and blood vessels. there are nerves around the prostate that affect sexual function, and damage to these nerves can lead to complications like sexual dysfunction and incontinence. therefore, how to completely remove the tumor, as far as possible to preserve these nerves, become an important issue in the surgical treatment. this study is aim to evaluate the different among nerve-sparing strategies, including unilateral intrafascial resection, bilateral intrafascial resection and bilateral extrafascial resection, on oncological outcome and functional recovery, so as to provide clinical evidence for nerve-sparing surgery of prostate cancer via robot-assisted posterior approach.

Eligibility criteria:
inclusion criteria: * men aged ≥18 years and ≤80 years; * histologically proven prostate adenocarcinoma with clinical stage \< t3(no capsule break) * clinically localized prostate cancer in very low, low, or intermediate risk groups according to national comprehensive cancer network(nccn) guidelines (2019 v4) ; * eastern cooperative oncology group(ecog) score of 0 or 1; * life expectancy greater than 10 years; * patients who are willing to accept robot-assisted radical prostatectomy after informed existing treatment plan, must sign the informed consent form. exclusion criteria: * surgeon thinks that the patient has an unresectable disease; * patients who have already applied androgen deprivation therapy(adt); * preoperative images suggest that the local lymph nodes were larger than 2 cm or suggest bone or distant metastasis; * any contraindication; * previous treatment of prostate cancer, including but not limited to surgery, hormone therapy, chemotherapy, radiotherapy, targeted therapy and immunotherapy; * patients with a history of transurethral resection or enucleation of the prostate; * severe systemic disease that may interfere with the data, assessment, or compliance; * patients who are participating in other clinical trials; * refusing to sign the informed consent * patients that are considered to be not suitable to be included by the researchers.
in turkish version "health care providers and impairment relationship scale (hc-pairs)"

Conditions: Chronic Low-back Pain; Health Personnel Attitude

Summary: the aim of this study was to determine the turkish validity and reliability of ''health care providers and impairment relationship scale hc (hc-pairs)'' developed by dr rainville.

low back pain is one of the reasons for applying to health institutions. low back pain, which seriously affects patients' lives and leads to major financial losses, causes serious deficiencies in both developing and developed countries. health professionals' perception of pain, factors associated with pain and fear avoidance attitudes of patients affect the success of treatment. the aim of this study is to determine the turkish version, validity and reliability of ''health care providers and impairment relationship scale (hc-pairs)''. 165 physiotherapist working with chronic low back pain were included in the study. in order to determine the reliability of the scale, the intraclass correlation coefficient (icc) will be used to determine the level of the relationship between the results of the first and second measurements. cronbach's alpha coefficient will be used for homogeneity of the questions in the scale. for concurrent validity, correlation coefficient will be used to determine the agreement between the previously validated scales and the turkish version of hc pairs.

Eligibility criteria:
inclusion criteria: * graduate with a bachelor's degree in physiotherapy and rehabilitation * to have worked in patients with chronic low back pain exclusion criteria: * not having experience in the clinic about low back pain

Keywords: validity, reliability, turkish version, hc-pairs
remembered meal satisfaction, satiety and later snack food intake

Conditions: Overweight and Obesity

Summary: this study examined whether remembered meal satisfaction (encompassing memory for meal liking and satiety) can be manipulated in the laboratory and whether this influences later food intake.

this study examined whether remembered meal satisfaction (encompassing memory for meal liking and satiety) can be manipulated in the laboratory and whether this influences later food intake. in a between-subjects design participants consumed a fixed lunch and then rehearsed the satisfying or dissatisfying aspects of the meal, or a neutral experience (control), in order to manipulate memory for meal satisfaction. three hours later, in a second visit to the laboratory, participants completed a bogus taste-test to measure food intake and meal memory measures.

Eligibility criteria:
inclusion criteria: * fluent english * not taking medication that affects appetite * no known history of food allergies or disordered eating

Keywords: food intake memory remembered satisfaction memory for recent eating satiety eating behavior